Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023 02 20; 41(6):1307-1317.

View in: PubMed

subject areas

Androgen Antagonists
Humans
Male
Neoplasm Recurrence, Local
Prostate
Prostatectomy
Prostate-Specific Antigen
Prostatic Neoplasms
Salvage Therapy

authors with profiles

Stanley Liauw